{"id":"NCT04852679","sponsor":"Ipsen","briefTitle":"Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs","officialTitle":"A Phase 3, Single-arm, Open-label, Multicentre Study to Assess the Efficacy and Safety of Deep Subcutaneous Injections of Lanreotide Autogel® 120 mg Administered Every 28 Days in Chinese Participants With Unresectable, Locally Advanced or Metastatic Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-05-24","primaryCompletion":"2022-06-10","completion":"2023-01-13","firstPosted":"2021-04-21","resultsPosted":"2024-10-01","lastUpdate":"2024-10-01"},"enrollment":43,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gastroenteropancreatic Neuroendocrine Tumor"],"interventions":[{"type":"DRUG","name":"Lanreotide autogel","otherNames":[]}],"arms":[{"label":"lanreotide Autogel 120 mg","type":"OTHER"}],"summary":"This study will be conducted to support the registration of the lanreotide Autogel 120 mg formulation in China for the treatment of GEP-NETs and treatment of clinical symptoms of NETs.\n\nThe study will include a screening period of up to 4 weeks followed by a 48-week intervention period. After completion of the main study period, five participants will continue in a self/partner injection cohort with lanreotide Autogel 120 mg every 28 days for 24 weeks.","primaryOutcome":{"measure":"Clinical Benefit Rate (CBR) of Tumour Response Assessed by Blinded Independent Central Review (BICR) at Week 24","timeFrame":"RECIST assessments performed at baseline (within 28 days before start of study intervention) and Weeks 24","effectByArm":[{"arm":"Lanreotide Autogel 120 mg","deltaMin":62.79,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":14,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":43},"commonTop":["Diarrhoea","Alanine aminotransferase increased","Bilirubin conjugated increased","Blood bilirubin increased","Weight decreased"]}}